ingredient Olaparib 50mg
substitutes Olanib 50mg 112s, Lynparza 50mg 112s
treatment Advanced Ovarian Cancer
Shipping class Room Temperature
Medicine Overview by Anukar Pharmacy
( Lynparza 50mg 112s Capsules, AstraZeneca )
TreatmentLynparza 50mg is a prescription medicine used to treat adult women who are in advanced ovarian cancer stage.
Side EffectsDecreased hemoglobin, Fatigue/asthenia, Nausea, Mean corpuscular volume elevation, Decreased lymphocytes, Abdominal pain/discomfort, Vomiting, Anemia, Diarrhea, Increased serum creatinine, Decreased platelets, Nasopharyngitis/URTI, Dyspepsia, Decrease ANC, Decreased appetite, Myalgia, Arthralgia/musculoskeletal pain, Hypersensitivity (rash, dermatitis), Cough, Thrombocytopenia, Dysgeusia, Lymphopenia, Dizziness, Stomatitis, Upper abdominal pain.
Method of UseFor advanced Ovarian cancer, 8 capsules twice daily (400 mg per dose) with or without food. Lynparza 50mg dosages must be taken according to professional physicians instructions. Dosages may vary according to patient conditions.
How Lynparza 50mg 112s Capsules, AstraZeneca WorksOlaparib is an anticancer medication. It works by stopping Poly-ADP-ribose polymerase (PARP) from working. PARP is a protein that helps cancer cells to repair themselves and continue to survive.
More Info by Anukar Pharmacy
( Lynparza 50mg 112s Capsules, AstraZeneca )
Suggestions
- Pneumonitis, including fatal cases, occurred in <1%; interrupt treatment if pneumonitis is suspected; discontinue if pneumonitis is confirmed.
- Incidence of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in clinical trials, including long-term follow up, was <1.5% (21/1680).
- Majority of MDS/AML cases had a fatal outcome; of these, 19/21 patients had a documented BRCA mutation, 1 patient had gBRCA wild-type and in 1 patient the BRCA mutation status was unknown.
- Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment.
- Do not initiate treatment until hematological toxicity caused by previous chemotherapy (CTCAE Grade ≤1) resolves.
- For prolonged hematological toxicities, interrupt treatment and promptly assess source of symptoms; monitor blood counts weekly until recovery.
- If levels have not recovered to CTCAE Grade ≤1 after 4 weeks, refer to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.
- All patients with myelodysplastic syndrome reported to have received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy; some of these patients also had a history of more than one primary malignancy or of bone marrow dysplasia.
- If MDS/AML is confirmed, discontinue olaparib.
- Clinical studies of olaparib in combination with other myelosuppressive anticancer agents (eg, DNA damaging agents) indicate a potentiation and prolongation of myelosuppressive toxicity.
- CYP3A4 inhibitors.
- Olaparib is a CYP3A4 substrate; coadministration of strong or moderate CYP3A4 inhibitors may increase olaparib plasma concentrations.
- Avoid concomitant use of strong or moderate CYP3A inhibitors.
- If strong or moderate CYP3A inhibitors must be coadministered, reduce dose of olaparib.
- Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during olaparib treatment since they are CYP3A inhibitors.
Warning by Anukar Pharmacy
( Lynparza 50mg 112s Capsules, AstraZeneca )
Special precautions for Lynparza 50mg 112s Capsules, AstraZeneca Heads up
| aspect | highlight | details |
|---|---|---|
Alcohol
|
caution | This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. |
Pregnancy
|
WEIGH RISKS VS BENEFITS | Can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. Please consult your doctor. |
Lactation
|
caution | Lynparza 50mg is probably unsafe to use during lactation. Limited human data suggest that the drug could represent a significant risk to the baby. |
Driving
|
It is not known whether Lynparza 50mg alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react. | |
Kidney
|
Lynparza 50mg is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Lynparza 50mg may not be needed in these patients. Please consult your doctor. | |
Liver
|
There is limited information available on the use of Lynparza 50mg in patients with liver disease. Please consult your doctor. |
Suggestion by Anukar Pharmacy on missing a dose
( Lynparza 50mg 112s Capsules, AstraZeneca )
If you miss a dose of Lynparza 50mg, please consult your doctor. Do not double the dose.
Disclaimer
The information of Anukar Pharmacy is for reference purpose only, and Anukar Pharmacy or Anukar Pharmacy or Anukar Pharmacy is not intended to be a replacement of professional medical advice, diagnosis, or treatment. Anukar Pharmacy suggest to ask the advice of a physician or any qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of anything you have learned from Anukar Pharmacy.
